Somatostatin Analogs: The Economic Value of Lanreotide Autogel Delivery Attributes in the Treatment of GEP-NET versus Octreotide LAR – A UK Budget Impact Analysis
Introduction: Lanreotide autogel (LAN) and octreotide long acting release (OCT) are long-acting somatostatin analogues (LA-SSAs) used to treat patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, the treatments differ in terms of injection route, need for administration by a health care professional and dosing interval.
Aim(s): To assess the budget impact of LA-SSAs in the treatment of GEP-NETs considering attributes related to the drug delivery of LA-SSAs in the UK.
Materials and methods: A decision tree was developed considering the following delivery attributes of LAN and OCT: nurse administration time (2.5 vs 6.2 min, respectively); risk of needle clogging (0% vs 2.6%, respectively); dosing interval (26% LAN pts vs 9% OCT pts treated every 3 weeks instead of every 4 weeks) and percent of pts who self-inject (10% vs 0%, respectively). Unit costs were taken from the NICE BNF and the NHS national tariff. The base case analysis compared the current and a hypothetical situation (50% vs 70% market share for LAN, respectively). Deterministic sensitivity analysis were conducted to account for potential increase of self-injection with LAN new delivery system (40%) and extended dose interval in pts with carcinoid syndrome (30%).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Feuilly M
To read the full abstract, please log into your ENETS Member account.